Literature DB >> 14671812

[Oncologic pharmacotherapy of elderly patients].

U Wedding1, U Merkel, K Farker, K Höffken.   

Abstract

Age is the major risk factor for the development of cancer. Difficulties in medical treatment of elderly patients with cancer may be due to age dependent changes in physiological organ function, which result in pharmacokinetical and pharmacodynamical changes. They also may be due to co-morbidities with the need of pharmacological therapy. The choice of adequate treatment protocols has to consider this age dependent changes in pharmacokinetics and the presence of co-morbidities. Most of the data reporting results of medical oncological treatment in patients with cancer are collected in younger patients. Therefore, the present knowledge concerning medical oncological treatment of elderly patients with cancer is still limited.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14671812     DOI: 10.1007/s00108-003-0943-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  25 in total

Review 1.  Age and the cardiovascular system.

Authors:  J Y Wei
Journal:  N Engl J Med       Date:  1992-12-10       Impact factor: 91.245

Review 2.  Antineoplastic chemotherapy of the older cancer patient.

Authors:  L Balducci; M B Corcoran
Journal:  Hematol Oncol Clin North Am       Date:  2000-02       Impact factor: 3.722

3.  The pulmonary toxicity of antineoplastic agents.

Authors:  S J Ginsberg; R L Comis
Journal:  Semin Oncol       Date:  1982-03       Impact factor: 4.929

4.  High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency.

Authors:  G A Smith; L E Damon; H S Rugo; C A Ries; C A Linker
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

Review 5.  Cancer chemotherapy in older adults. A tolerability perspective.

Authors:  G G Kimmick; R Fleming; H B Muss; L Balducci
Journal:  Drugs Aging       Date:  1997-01       Impact factor: 3.923

6.  Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial.

Authors:  B N Stein; N J Petrelli; H O Douglass; D L Driscoll; G Arcangeli; N J Meropol
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

7.  Risk factors for doxorubicin-induced congestive heart failure.

Authors:  D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

8.  Lack of age-dependent cisplatin nephrotoxicity.

Authors:  W J Hrushesky; W Shimp; B J Kennedy
Journal:  Am J Med       Date:  1984-04       Impact factor: 4.965

9.  The effect of comorbidity on 3-year survival of women with primary breast cancer.

Authors:  W A Satariano; D R Ragland
Journal:  Ann Intern Med       Date:  1994-01-15       Impact factor: 25.391

Review 10.  Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results.

Authors:  F Leoni; S Ciolli; G Giuliani; A Pascarella; R Caporale; F Salti; L Cervi; P Rossi Ferrini
Journal:  Br J Haematol       Date:  1995-05       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.